Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes

Cytometry Part A

Volumn 75, Issue 3, 2009, Pages 253-263

  Young, Susan M ^a   Bologa, Cristian M ^a   Fara, Dan ^a   Bryant, Bj K ^b   Strouse, Juan Jacob ^a   Arterburn, Jeffrey B ^b   Ye, Richard D ^c   Oprea, Tudor I ^a   Prossnitz, Eric R ^a   Sklar, Larry A ^a,d   Edwards, Bruce S ^a,d,e  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b NEW MEXICO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Flow cytometry; Formylpeptide receptor; Formylpeptide receptor like 1; G protein coupled receptors; High throughput screening

Indexed keywords

CALCIUM; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR LIKE 1;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELLS, CULTURED; CHEMOTACTIC FACTORS; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; LIGANDS; MOLECULAR PROBES; RATS; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; SENSITIVITY AND SPECIFICITY; U937 CELLS;

EID: 65349097903     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20645     Document Type: Article

References (56)

1. Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol 2002;23:541-548.
2. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol 1991;9:617-648.
3. Murphy PM. The N-formylpeptide chemotactic receptor. In: Horuk R, editor. Chemoattractant Ligands and Their Receptors. Boca Raton, FL: CRC Press; 1996. pp 269-299.
4. Le Y, Oppenheim JJ, Wang JM. Pleiotropic roles of formyl peptide receptors. Cyto-kine Growth FactorRev2001;12:91-105.
5. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu RevImmunol1994;12:593-633.
6. He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G protein-coupledreceptor, FPRL1/LXA4R. Blood2003;101:1572-1581.
7. Tiffany HL, Lavigne MC, Cui YH, Wang JM, Leto TL, Gao JL, Murphy PM. Amyloid- β induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain. J Biol Chem 2001;276:23645-23652.
8. Schiffmann E, Showell HV, Corcoran BA, Ward PA, Smith E, Becker EL. The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J Immunol1975;114:1831-1837.
9. Schiffmann E, Corcoran BA, Wahl SM. N-formylmethionyl peptides as chemoattrac-tantsforleucocytes. Proc NatlAcad Sci USA 1975;72:1059-1062.
10. Marasco WA, Phan SH, Krutzsch H, Showell HJ, Feltner DE, Nairn R, Becker EL, Ward PA. Purification and identification of formyl-methionyl-leucyl- phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem 1984;259:5430-5439.
11. Carp H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutro-phils. J Exp Med 1982;155:264-275.
12. Gao JL, Lee EJ, Murphy PM. Impaired antibacterial host defense in mice lacking the N-formylpeptidereceptor.JExpMed1999;189:657-662.
13. Walther A, Riehemann K, Gerke V. A novel ligand of the formyl peptide receptor: Annexin I regulates neutrophil extravasation by interacting with the FPR. Mol Cell 2000;5:831-840.
14. Zhou Y, Bian X, Le Y, Gong W, Hu J, Zhang X, Wang L, Iribarren P, Salcedo R, Howard OM, et al. Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer Inst 2005;97:823-835.
15. Yao XH, Ping YF, Chen JH, Chen DL, Xu CP, Zheng J, Wang JM, Bian XW. Production of angiogenic factors by human glioblastoma cells following activation of the G- protein coupled formylpeptide receptor FPR. J Neurooncol 2008;86:47-53.
16. BaoL,GerardNP, EddyRLJr, ShowsTB,GerardC. Mappingofgenesforthehuman C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homo- logue orphan receptors (FPRH1, FPRH2) to chromosome 19. Genomics 1992; 13:437-440.
17. Murphy PM, Ozcelik T, Kenney RT, Tiffany HL, McDermott D, Francke U. A structural homologue of the N-formyl peptide receptor. Characterization and chromosome mapping of a peptide chemoattractant receptor family. J Biol Chem 1992; 267:7637-7643.
18. Ye RD, Cavanagh SL, Quehenberger O, Prossnitz ER, Cochrane CG. Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor. Biochem Biophys Res Commun 1992;184:582-589.
19. Nomura H, Nielsen BW, Matsushima K. Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. Int Immunol 1993;5:1239-1249.
20. Prossnitz ER, Ye RD. The N-formylpeptide receptor: Amodelfor the studyofche- moattractantreceptorstructureand function. Pharmacol Ther1997;74:73-102.
21. Su SB, Gong W, Gao JL, Shen W, Murphy PM, Oppenheim JJ, Wang JM. A seven- transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 1999;189:395-402.
22. Le Y,Gong W,Tiffany HL,Tumanov A,Nedospasov S,Shen W,Dunlop NM,Gao JL, Murphy PM, Oppenheim JJ, et al. Amyloid (β)42 activates a G-protein-coupled che- moattractant receptor, FPR-like-1. J Neurosci 2001;21:RC123.
23. Le Y, Yazawa H, Gong W, Yu Z, Ferrans VJ, Murphy PM, Wang JM. The neurotoxic prion peptide fragment PrP (106-126) is a chemotactic agonist for the G protein- coupled receptor formyl peptide receptor-like 1. J Immunol 2001;166:1448-1451.
24. Snipe JD. The acute phase response. In: Oppenheim JJ, Shevac EM, editors. Immuno-physiology: The Role of Cells and Cytokines in Immunity and Inflammation. New York, NY: Oxford University Press; 1990. pp 259-273.
25. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95:6448-6453.
26. Kalaria RN. Microglia and Alzheimer's disease. Curr Opin Hematol 1999;6:15-24.
27. Brown DR, Schmidt B, Kretzschmar HA. Role of microglia and host prion protein in neurotoxicityof a prion protein fragment. Nature 1996;380:345-347.
28. Le Y, Yang Y, Cui Y, Yazawa H, Gong W, Qiu C, Wang JM. Receptors for chemotactic formyl peptides as pharmacological targets. Int Immunopharmacol 2002;2:1-13.
29. Yazawa H, Yu ZX, Takeda, Le Y, Gong W, Ferrans VJ, Oppenheim JJ, Li CC, Wang JM. β amyloid peptide (Aβ42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J 2001;15:2454-2462.
30. De Y, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ, Cher-tov O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formylpeptidereceptor-like1 (FPRL1) asareceptortochemoattracthumanperiph- eralbloodneutrophils, monocytes, andTcells. J Exp Med2000;192:1069-1074.
31. Chiang N, Fierro IM, Gronert K, Serhan CN. Activation oflipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med 2000;191:1197-1208.
32. Su SB, Gao J, Gong W, Dunlop NM, Murphy PM, Oppenheim JJ, Wang JM. T21/DP107, a synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors. J Immunol 1999;162:5924-5930.
33. Le Y, Jiang S, Hu J, Gong W, Su S, Dunlop NM, Shen W, Li B, Ming Wang J. N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator ofhuman phagocytes. Clin Immunol 2000;96:236-242.
34. VanCompernolle SE, Clark KL, Rummel KA, Todd SC. Expression and function of formyl peptide receptors on human fibroblast cells. J Immunol 2003;171:2050-2056.
35. Lin C, Wei W, Zhang J, Liu S, Liu Y, Zheng D. Formyl peptide receptor-like 1 mediated endogenous TRAIL gene expression with tumoricidal activity. Mol Cancer Ther2007;6:2618-2625.
36. McCoy R, Haviland DL, Molmenti EP, Ziambaras T, Wetsel RA, Perlmutter DH. N- formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation. J Exp Med 1995;182:207-217.
37. Sozzani S, Sallusto F, Luini W, Zhou D, Piemonti L, Allavena P, Van Damme J, Vali- tutti S, Lanzavecchia A, Mantovani A. Migration of dendritic cells in response to for- myl peptides, C5a, and a distinct set of chemokines. J Immunol 1995;155:3292-3295.
38. Lacy M, Jones J, Whittemore SR, Haviland DL, Wetsel RA, Barnum SR. Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astro- cytesand microglia. J Neuroimmunol1995;61:71-78.
39. Keitoku M, Kohzuki M, Katoh H, Funakoshi M, Suzuki S, Takeuchi M, Karibe A, Horiguchi S, Watanabe J, Satoh S, et al. FMLP actions and its binding sites in isolated human coronary arteries. J Mol Cell Cardiol 1997;29:881-894.
40. Gronert K, Gewirtz A, Madara JL, Serhan CN. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon y and inhibits tumor necrosis factor a-induced IL-8 release. J Exp Med 1998;187:1285-1294.
41. Le Y, Hu J, Gong W, Shen W, Li B, Dunlop NM, Halverson DO, Blair DG, Wang JM. Expression of functional formyl peptide receptors by human astrocytoma cell lines. J Neuroimmunol 2000;111:102-108.
42. Edwards BS, Bologa C, Young SM, Balakin KV, Prossnitz E, Savchuck NP, Sklar LA, Oprea TI. Integration of virtual screening with high throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol Pharmacol 2005;68:1301-1310.
43. Burli RW, Xu H, Zou X, Muller K, Golden J, Frohn M, Adlam M, Plant MH, Wong M, McElvain M, et al. Potent hFPRL1 (ALXR) agonists as potential anti-inflamma- toryagents. Bioorg Med Chem Lett 2006;16:3713-3718.
44. Nanamori M, Cheng X, Mei J, Sang H, Xuan Y, Zhou C, Wang MW, Ye RD. A novel nonpeptide ligand for formyl peptide receptor-like 1. Mol Pharmacol 2004;66:1213-1222.
45. Zhou C, Zhang S, Nanamori M, Zhang Y, Liu Q, Li N, Sun M, Tian J, Ye PP, Cheng N, et al. Pharmacological characterization of a novel nonpeptide antagonist for for- mylpeptidereceptor-like1. MolPharmacol2007;72:976-983.
46. Ramirez S, Aiken CT, Andrzejewski B, Sklar LA, Edwards BS. High-throughput flow cytometry: Validation in micro volume bioassays. Cytometry Part A 2003;53A:55-65.
47. Kuckuck FW, Edwards BS, Sklar LA. High throughput flow cytometry. Cytometry 2001;44:83-90.
48. Munson PJ, Rodbard D. An exact correction to the "Cheng- Prusoff" correction. J Recept Res 1988;8:533-546.
49. Young SM, Bologa C, Prossnitz E, Oprea TI, Sklar LA, Edwards BS. High throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands. J Biomol Screen 2005;10:374-382.
50. Schepetkin IA, Kirpotina LN, KhlebnikovAI, Quinn MT. High-throughput screening for small-molecule activators of neutrophils: Identification of novel N-formyl peptide receptor agonists. Mol Pharmacol 2007;71:1061-1074.
51. Schepetkin IA, Kirpotina LN, Tian J, Khlebnikov AI, Ye RD, Quinn MT. Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factora production. Mol Pharmacol 2008;74:392-402.
52. Kettman JR, Davies T, Chandler D, Oliver KG, Fulton RJ. Classification and properties of 64 multiplexed microsphere sets. Cytometry 1998;33:234-243.
53. Nolan JP, Sklar LA. Suspension array technology: Evolution of the flat-array paradigm. TrendsBiotechnol 2002;20:9-12.
54. Shapiro HM. Practical Flow Cytometry. New York: Alan R. Liss; 1988.
55. Perez OD, Nolan GP. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat Biotechnol 2002;20:155-162.
56. Krutzik PO, Nolan GP. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods 2006;3:361-368.